Join
Live feed
·
PRReleasevia Quantisnow
Relay Therapeutics Inc. logo

Relay Therapeutics Announces Preclinical Data that Support RLY-2608 as the First Known Allosteric Pan-Mutant Selective Inhibitor of PI3Kα

ByQuantisnow·Wall Street's wire, on your screen.
RLAY· Relay Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RLAY (Relay Therapeutics Inc.) and more on Quantisnow.